Compare CIB & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIB | ASND |
|---|---|---|
| Founded | 1945 | 2006 |
| Country | Colombia | Denmark |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 15.2B |
| IPO Year | 2025 | 2014 |
| Metric | CIB | ASND |
|---|---|---|
| Price | $81.23 | $231.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $70.25 | ★ $281.50 |
| AVG Volume (30 Days) | 436.5K | ★ 533.7K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.74 | $96.35 |
| Revenue Next Year | $8.05 | $44.91 |
| P/E Ratio | $10.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.20 | $161.09 |
| 52 Week High | $86.31 | $250.74 |
| Indicator | CIB | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 71.24 | 54.46 |
| Support Level | $61.61 | $213.28 |
| Resistance Level | $83.13 | $236.58 |
| Average True Range (ATR) | 2.56 | 8.51 |
| MACD | 0.86 | 1.92 |
| Stochastic Oscillator | 90.97 | 81.42 |
Grupo Cibest SA is a full service financial group offering a broad range of financial products and services to a diversified individual and corporate clients through subsidiaries. Its network also includes offshore banking subsidiaries in Panama and Puerto Rico, as well as other adjacent businesses. Its products and services include Savings and Investment, Financing, Factoring, Financial and Operating Leases, Capital Markets, Trading, Cash Management, Foreign Currency and Trade Finance, Bancassurance and Insurance, Investment Banking, Trust and Fiduciary Services, Mortgage Lending Business, among others. Its segments include Banking Colombia, Banking El Salvador, Banking Guatemala, International Banking, Leases, All Other and Banking Panama.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.